30 results
To compare PFS of subjects with newly-diagnosed MGMT methylated or indeterminate GBM subtypes treated with RT plus TMZ combined with nivolumab or placebo. PFS will be determined by BICR based on RANO criteria.To compare OS of subjects with newly-…
Part A: To characterize the safety, tolerability, and define the MTD or RP2D for the combination of relatlimab + nivolumab in pediatric participants less than 18 years of age with R/R cHL and NHL.Part A: To characterize the PK of relatlimab for the…
The primary objective is to determine the safety, tolerability, dose-limiting toxicities (DLTs), and maximum tolerated dose (MTD) of BMS-986016 administered alone and in combination with nivolumab in subjects with advanced solid tumors.The co-…
Main objectiveImprovement of 1-yr PFS by nivolumab plus (R)-GemOx followed by nivolumab consolidation instead of (R)-GemOx alone in patients withprogressed or relapsed aggressive NHLs not eligible neither for autologous nor allogeneic stem cell…
To determine the activity and safety of nivolumab (as monotherapy or in combination with other immunomodulatory treatments) after different immune response induction treatments in TNBC patients with metastatic disease.
Primary objectiveTo determine the pathological complete response rate per cohort
Primary objectivePhase I: To determine the recommended phase II dose (RP2D) of the combination treatment with nivolumab and entinostat administered to adolescents 12-21 years with progressive, relapsed , refractory high-risk solid tumors and CNS…
The main purpose of this study is to assess investigate the effect of encorafenib and binimetinib (the study drugs) on the activity of other common drugs and the effect of modafinil on the activity of encorafenib. The study will also look at the…
Main objective: To assess PFS rate at 6 months in patients treated with nivolumab or the combination of nivolumab and ipilimumab, with relapsed/advanced thymic carcinoma and type B3 thymoma not amenable to curative-intent radical treatment and…
Main objectives:• To evaluate whole body distribution of 89Zr-Df-crefmirlimab in cancer patients prior to and during treatment with an anti-PD-1 antibody.• To evaluate pharmacokinetics (PK) of 89Zr-Df-crefmirlimab in patients prior to and during…